Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 3/20 | 0.56 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.56 |
| ▸ | HSD17B7 | P56937 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5408042 | 1.00 | SRD5A1 (0.56) | SRD5A1SRD5A2HSD17B7 | |
| SCHEMBL14561091 | 1.00 | SRD5A1 (0.56) | SRD5A1SRD5A2HSD17B7 | |
| SCHEMBL11139764 | 0.85 | SRD5A1 (0.53) | SRD5A1SRD5A2 | |
| SCHEMBL11139762 | 0.85 | SRD5A1 (0.53) | SRD5A1SRD5A2 | |
| SCHEMBL11139760 | 0.85 | SRD5A1 (0.53) | SRD5A1SRD5A2 | |
| SCHEMBL7529348 | 0.84 | HSD17B7 (0.60) | SRD5A1SRD5A2HSD17B7 | |
| SCHEMBL7527383 | 0.84 | HSD17B7 (0.60) | SRD5A1SRD5A2HSD17B7 | |
| SCHEMBL13656757 | 0.84 | HSD17B7 (0.60) | SRD5A1SRD5A2HSD17B7 | |
| SCHEMBL7527375 | 0.84 | HSD17B7 (0.60) | SRD5A1SRD5A2HSD17B7 | |
| SCHEMBL9115297 | 0.83 | SRD5A1 (0.49) | SRD5A1SRD5A2HSD17B7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186728-B2 | Methylene-4-azasteroids | SCHERING AG (DE) | 2007-03-06 | — | — | US | claimed |
| EP-1409513-B1 | METHYLENE-4-AZASTEROIDS | SCHERING AG (DE) | 2006-04-12 | — | — | EP | claimed |
| US-20040248921-A1 | Methylene-4-azasteroids | SCHERING AG (DE) | 2004-12-09 | — | — | US | claimed |
| EP-1409513-A1 | METHYLENE-4-AZASTEROIDS | Schering AG (DE) | 2004-04-21 | — | — | EP | claimed |
| WO-2003020744-A1 | METHYLENE-4-AZASTEROIDS | SCHERING AG (DE) | 2003-03-13 | — | — | WO | claimed |
| US-7186728-B2 | Methylene-4-azasteroids | SCHERING AG (DE) | 2007-03-06 | — | — | US | disclosed |
| EP-1409513-B1 | METHYLENE-4-AZASTEROIDS | SCHERING AG (DE) | 2006-04-12 | — | — | EP | disclosed |
| US-20040248921-A1 | Methylene-4-azasteroids | SCHERING AG (DE) | 2004-12-09 | — | — | US | disclosed |
| EP-1409513-A1 | METHYLENE-4-AZASTEROIDS | Schering AG (DE) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003020744-A1 | METHYLENE-4-AZASTEROIDS | SCHERING AG (DE) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248921-A1 | Methylene-4-azasteroids | CYP17A1, NR5A1, HSD3B1 | SRD5A1 8/4885SRD5A2 6/4885HSD17B7 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.